[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 6 of about 6
1. Johansen SS, Karkov J: A fatal overdose of the ergot derivative cabergoline. Forensic Sci Int; 2004 Nov 10;146(1):47-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Autopsy showed an extrahepatic bile duct adenocarcinoma with spread to the gall bladder, the liver, and regional lymphnodes.
  • Biological samples obtained at the autopsy were screened for common drugs and narcotics.
  • Several drugs such as buprenorphine, codeine, paracetamol, and propranolol were detected in the blood at therapeutic levels.
  • [MeSH-major] Antiparkinson Agents / poisoning. Ergolines / poisoning
  • [MeSH-minor] Aged. Chromatography, Ion Exchange. Drug Overdose. Female. Gas Chromatography-Mass Spectrometry. Humans. Liver / chemistry. Molecular Structure. Parkinson Disease / drug therapy. Spectrometry, Mass, Electrospray Ionization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15485721.001).
  • [ISSN] 0379-0738
  • [Journal-full-title] Forensic science international
  • [ISO-abbreviation] Forensic Sci. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 0 / Ergolines; LL60K9J05T / cabergoline
  •  go-up   go-down


2. Aldrighetti L, Arru M, Ronzoni M, Salvioni M, Villa E, Ferla G: Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer. Hepatogastroenterology; 2001 Sep-Oct;48(41):1302-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer.
  • Hepatic arterial infusion of floxuridine is an effective treatment for unresectable hepatic metastases from colorectal cancer.
  • Despite its pharmacological advantage of higher tumor drug concentration with minimal systemic toxicity, hepatic arterial infusion of floxuridine is characterized by regional toxicity, including hepatobiliary damage resembling idiopathic sclerosing cholangitis (5-29% of treated cases).
  • Unlike previous reports describing biliary damage of both intrahepatic and extrahepatic ducts, a case series of extrahepatic biliary stenosis after hepatic arterial infusion with floxuridine is herein described.
  • They received from 9 to 19 cycles (mean 14.5 +/- 6.3 cycles) of floxuridine infusion with a total drug delivered dose ranging from 20.3 to 41.02 mg/kg (mean: 31.4 +/- 13.5 mg/kg).
  • Extrahepatic biliary sclerosis was discovered by computed tomography scan and ultrasound, followed by endoscopic retrograde cholangiopancreatography and/or percutaneous cholangiography in 3 cases.
  • Radiological findings included common hepatic duct complete obstruction in 1 case, common hepatic duct stenosis in 2 cases, common bile duct obstruction in 1 case, and intrahepatic bile ducts dilation without a well-recognized obstruction in 1 case.
  • The present series suggests that in some patients receiving hepatic arterial infusion of floxuridine extrahepatic biliary stenosis may represent the primary event leading to a secondary intrahepatic biliary damage that does not correlate with specific floxuridine toxicity but results from bile stasis and infection, recurrent cholangitis and eventually biliary sclerosis.
  • Aggressive research for extrahepatic biliary sclerosis is advised, since an early nonsurgical treatment of extrahepatic biliary stenosis may prevent an irreversible intrahepatic biliary sclerosis worsening the prognosis of metastatic liver disease.
  • [MeSH-major] Adenocarcinoma / secondary. Cholestasis, Extrahepatic / chemically induced. Colorectal Neoplasms / drug therapy. Floxuridine / adverse effects. Infusions, Intra-Arterial. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Cholangiography. Cholangitis, Sclerosing / chemically induced. Cholangitis, Sclerosing / diagnosis. Cholangitis, Sclerosing / therapy. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Liver Function Tests. Male. Middle Aged. Stents


3. Park I, Lee JL, Ryu MH, Kim TW, Chang HM, Lee SS, Sohn BS, Kim EK, Park DH, Lee SS, Suh DW, Lee SK, Kim MH, Lee J: Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients. Oncology; 2009;76(2):126-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients.
  • AIM: We investigated the efficacy and safety of S-1 monotherapy for the treatment of advanced biliary tract adenocarcinoma (BTA) in a clinical practice setting.
  • The primary tumors were intrahepatic (n = 57), in the gall bladder (n = 50), in extrahepatic bile ducts (n = 41) and in the ampulla of Vater (n = 14).
  • Response rates and survival differed significantly according to the primary site of the tumor (p = 0.002 and p < 0.001, respectively), with extrahepatic bile duct adenocarcinoma having the best prognosis.
  • The efficacy of S-1 against advanced BTA depends on the tumor site and is most effective in patients with extrahepatic BTA.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biliary Tract Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Cohort Studies. Drug Combinations. Drug Delivery Systems. Female. Humans. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19158445.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


Advertisement
4. Jievaltas M, Jasenas M, Drigotas M, Barauskas G, Pundzius J: Results of treatment of extrahepatic cholangiocarcinoma at Kaunas University of Medicine Hospital. Medicina (Kaunas); 2003;39(2):144-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment of extrahepatic cholangiocarcinoma at Kaunas University of Medicine Hospital.
  • Adenocarcinoma of the extrahepatic bile ducts is considered to be a rare cause of obstructive jaundice.
  • The aim of study was to evaluate the outcome of treatment of patients having extrahepatic carcinoma of the bile ducts.
  • Patients underwent treatment at Kaunas University of Medicine Hospital.
  • A retrospective study was performed of 57 patients suffering from cancer of extrahepatic bile ducts in 1996-2001.
  • Diagnosis was established by ultrasonography, endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangiography and computed tomography.
  • Eight patients (14%) underwent radical resections of bile ducts: five patients had resections of bile ducts with D2 lymphonodectomy, two patients had bile duct resections in combination with pancreatoduodenal resection and one patient had resection of the bile ducts in combination with right hepatectomy.
  • Recent progress made in surgical techniques and in perioperative management of extrahepatic cholangiocarcinomas as well as modern diagnostic achievements has greatly contributed to the outcomes of radical surgery.
  • The main aim of the treatment is to perform resection of the bile ducts cancer.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Extrahepatic. Cholangiocarcinoma / surgery

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12626867.001).
  • [ISSN] 1010-660X
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Lithuania
  •  go-up   go-down


5. Connolly L, Maxwell P: Image analysis of Transwell assays in the assessment of invasion by malignant cell lines. Br J Biomed Sci; 2002;59(1):11-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two cell lines from extrahepatic bile duct adenocarcinoma were tested in serum-free growth medium.
  • [MeSH-major] Adenocarcinoma / pathology. Bile Duct Neoplasms / pathology. Image Processing, Computer-Assisted. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Biomarkers. Collagen. Culture Media, Conditioned. Diffusion Chambers, Culture. Drug Combinations. Extracellular Matrix / pathology. Humans. Keratins / analysis. Laminin / analysis. Proteoglycans. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12000178.001).
  • [ISSN] 0967-4845
  • [Journal-full-title] British journal of biomedical science
  • [ISO-abbreviation] Br. J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / Culture Media, Conditioned; 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 119978-18-6 / matrigel; 68238-35-7 / Keratins; 9007-34-5 / Collagen
  •  go-up   go-down


6. Karakolios A, Kasapis C, Kallinikidis T, Kalpidis P, Grigoriadis N: Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma. Clin Gastroenterol Hepatol; 2003 Nov;1(6):480-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholestatic jaundice as a paraneoplastic manifestation of prostate adenocarcinoma.
  • Malignancies may cause cholestatic jaundice through well-recognized mechanisms (e.g., bile duct obstruction or widespread hepatic infiltration).
  • Prostate cancer presenting initially with cholestatic jaundice without any obvious cause (i.e., obstruction or infiltration) has been reported in 2 cases in the medical literature.
  • During the diagnostic work-up, prostate cancer was diagnosed.
  • The results of appropriate investigations performed during the patient's hospitalizations indicated no evidence of hepatic metastases or extrahepatic biliary obstruction.
  • Patients with unexplained cholestasis should be investigated for malignancies, including prostate cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Jaundice, Obstructive / diagnosis. Paraneoplastic Syndromes / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Alkaline Phosphatase / metabolism. Antineoplastic Agents, Hormonal / therapeutic use. Bilirubin / metabolism. Biomarkers, Tumor / analysis. Cholangiopancreatography, Endoscopic Retrograde. Diagnosis, Differential. Flutamide / therapeutic use. Humans. Leuprolide / therapeutic use. Male. Pruritus / diagnosis. Pruritus / drug therapy. Pruritus / metabolism. Tomography, X-Ray Computed. Transaminases / metabolism. gamma-Glutamyltransferase / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15017648.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 76W6J0943E / Flutamide; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.6.1.- / Transaminases; EC 3.1.3.1 / Alkaline Phosphatase; EFY6W0M8TG / Leuprolide; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down






Advertisement